{"id":45109,"date":"2016-10-30T00:00:00","date_gmt":"2016-10-30T04:00:00","guid":{"rendered":"https:\/\/asweetlife.org\/novo-nordisk-drops-oral-insulin-development-projects\/"},"modified":"2016-10-31T02:55:32","modified_gmt":"2016-10-31T06:55:32","slug":"novo-nordisk-drops-oral-insulin-development-projects","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=45109","title":{"rendered":"Novo Nordisk Drops Oral Insulin Development Projects"},"content":{"rendered":"<div><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2016\/10\/Novo_Nordisk-large-.png\" rel=\"mfp\"><img decoding=\"async\" class=\"wp-image-39309 size-thumbnail alignright lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2016\/10\/Novo_Nordisk-large--170x130.png\" alt=\"Novo Nordisk\" width=\"170\" height=\"130\" \/><\/a>According to an article published on <a href=\"http:\/\/seekingalpha.com\/\" target=\"_blank\">Seeking Alpha<\/a>, Novo Nordisk has decided to make some significant changes in its drug development strategy as a result of the\u00a0&#8216;current payment atmosphere\u2019 in which\u00a0patients are no longer willing to pay more for drugs that only incrementally improve efficacy.<\/div>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<div>\n<h3 class=\"m_421122287879476347m_-230606679047330746p m_421122287879476347m_-230606679047330746p1\">Novo Nordisk\u2019s revised R&amp;D strategy has three key parts:<\/h3>\n<ul class=\"m_421122287879476347m_-230606679047330746p m_421122287879476347m_-230606679047330746p1\">\n<li>apply a higher innovation threshold for diabetes projects<\/li>\n<li>increase the focus in areas of high unmet need including NASH, CVD (cardiovascular disease), and CKD (chronic kidney disease) that are adjacent to diabetes<\/li>\n<li>strengthen the early-stage portfolio through in-licensing and external academic collaborations.<\/li>\n<\/ul>\n<div>As part of this change in strategy the company has decided to drop its oral insulin development projects which have\u00a0been assessed not to be commercially viable in the increasingly challenging payer environment.<\/div>\n<\/div>\n<div>\u00a0<\/div>\n<div>\n<div>For the full article please go to\u00a0<a href=\"http:\/\/seekingalpha.com\/article\/4016755-new-novo-nordisk-strategy-drops-oral-insulin-expands-oral-glpminus-1\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?hl=en&amp;q=http:\/\/seekingalpha.com\/article\/4016755-new-novo-nordisk-strategy-drops-oral-insulin-expands-oral-glpminus-1&amp;source=gmail&amp;ust=1477915378181000&amp;usg=AFQjCNHNnoVgSyHoCjvM6zG8vYNyEI2bsQ\">Seeking Alpha<\/a>.<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>&hellip;<\/p>\n","protected":false},"author":131,"featured_media":38266,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441,1442],"tags":[311],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk Drops Oral Insulin Development Projects<\/title>\n<meta name=\"description\" content=\"As part of this change in strategy the company has decided to drop its oral insulin development projects which have been assessed not to be commercially viable in the increasingly challenging payer environment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=45109\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=45109\",\"url\":\"https:\/\/asweetlife.org\/?p=45109\",\"name\":\"Novo Nordisk Drops Oral Insulin Development Projects\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=45109#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=45109#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/09\/Novo_Nordisk-large-.png\",\"datePublished\":\"2016-10-30T04:00:00+00:00\",\"dateModified\":\"2016-10-31T06:55:32+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"As part of this change in strategy the company has decided to drop its oral insulin development projects which have been assessed not to be commercially viable in the increasingly challenging payer environment.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=45109#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=45109\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=45109#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/09\/Novo_Nordisk-large-.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/09\/Novo_Nordisk-large-.png\",\"width\":1280,\"height\":970,\"caption\":\"Novo Nordisk Rybelsus\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=45109#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Drops Oral Insulin Development Projects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Drops Oral Insulin Development Projects","description":"As part of this change in strategy the company has decided to drop its oral insulin development projects which have been assessed not to be commercially viable in the increasingly challenging payer environment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=45109","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=45109","url":"https:\/\/asweetlife.org\/?p=45109","name":"Novo Nordisk Drops Oral Insulin Development Projects","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=45109#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=45109#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/09\/Novo_Nordisk-large-.png","datePublished":"2016-10-30T04:00:00+00:00","dateModified":"2016-10-31T06:55:32+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"As part of this change in strategy the company has decided to drop its oral insulin development projects which have been assessed not to be commercially viable in the increasingly challenging payer environment.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=45109#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=45109"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=45109#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/09\/Novo_Nordisk-large-.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/09\/Novo_Nordisk-large-.png","width":1280,"height":970,"caption":"Novo Nordisk Rybelsus"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=45109#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Drops Oral Insulin Development Projects"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/45109"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45109"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/45109\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/38266"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}